AKT1 and cancer: Aberrant activation of the AKT‐mTOR (protein kinase B/mammalian target of rapamycin) cascade had been found in various cancers (Laplante, & Sabatini, 2012; Raphael, Desautels, Pritchard, Petkova, & Shah, 2018).